Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential
09. Januar 2025 08:00 ET
|
Frontier Medicines
FMC-220 is a first-in-class covalent activator of p53Y220C designed to address potency and tolerability challenges of non-covalent approachesIn preclinical studies, FMC-220 demonstrated unprecedented...
Frontier Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08. Januar 2025 17:13 ET
|
Frontier Medicines
BOSTON and SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation (“Frontier” or the “Company”), a clinical-stage precision medicine company unlocking to...
Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription Factor
23. Juli 2024 07:00 ET
|
Frontier Medicines
BOSTON and SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation (“Frontier” or the “Company”), a clinical-stage precision medicine company seeking to unlock...
Frontier Medicines Appoints Gerardo Ubaghs as Chief Financial Officer and Announces $20 Million Series C Extension
25. Juni 2024 07:00 ET
|
Frontier Medicines
Gerardo Ubaghs brings high-profile global biopharma strategic and capital markets experience as newly appointed Chief Financial Officer (CFO)Company adds $20 million to close oversubscribed Series C...
Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting
09. April 2024 16:30 ET
|
Frontier Medicines
- Pre-clinical results demonstrate the combination of FMC-376 with PD-1 immunotherapy increases survival and response rates compared to PD-1 alone - FMC-376 is broadly active in KRASG12C mutant...
Frontier Medicines to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2024
06. März 2024 08:00 ET
|
Frontier Medicines
BOSTON and SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical stage precision medicine company seeking to unlock the proteome to advance...
Frontier Medicines to Participate in Upcoming Investor Conferences
27. Februar 2024 08:00 ET
|
Frontier Medicines
BOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational...
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
22. Februar 2024 16:01 ET
|
Frontier Medicines
Frontier Medicines Series C close and first patient dosed
Frontier Medicines to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03. Januar 2024 07:00 ET
|
Frontier Medicines
BOSTON and SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational...
Frontier Medicines Announces Appointment of Andrew Krivoshik, M.D., Ph.D., as Chief Medical Officer
08. Mai 2023 08:00 ET
|
Frontier Medicines
BOSTON and SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational...